PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 30, 2026Journal of Clinical Oncology0 citations

Impact of clinical and treatment characteristics on fear of cancer recurrence and quality of life in survivors of early-stage breast cancer.

View Full Paper
NCNatalia CamejoCCCecilia CastilloDADahiana Amarillo

Key Points

  • The aim is to explore the prevalence of fear of cancer recurrence (FCR) and its association with quality of life in early-stage breast cancer survivors.
  • Conducted in two public centers with 301 women, stage I–III breast cancer, at least 12 months post-treatment.
  • Used the Cancer Worry Scale to assess FCR and PROMIS Global-10 for health-related quality of life.
  • Analyzed associations with clinical and sociodemographic characteristics.
  • 34.9% experienced high FCR, and 20.9% moderate; associated with diagnosis ≤5 years, age <50, education, chemotherapy, and endocrine therapy.
  • Median PROMIS Global-10 scores showed 37.4 for physical health and 43.5 for mental health.
  • Higher FCR linked to significantly poorer HRQoL across all domains (p < 0.001).

Abstract

e12684 Background: Fear of cancer recurrence (FCR) is one of the most frequent concerns among breast cancer survivors and can significantly affect health-related quality of life (HRQoL). However, it remains insufficiently explored in routine clinical practice. Objective: To describe the prevalence of FCR and HRQoL in patients with early breast cancer and to analyze their association with clinical and sociodemographic characteristics. Methods: An ambispective observational study was conducted in two public centers. A total of 301 women with stage I–III breast cancer, disease-free and at least 12 months post-treatment, were included. FCR was assessed using the Cancer Worry Scale, and HRQoL using the PROMIS Global-10 instrument. Results: High FCR was observed in 34.9% of participants, and moderate FCR in 20.9%. FCR was significantly associated with ≤5 years since diagnosis, age <50 years, education level, chemotherapy, and endocrine therapy. No associations were found with tumor stage, breast surgery type, axillary surgery, or radiotherapy. Nearly half of the patients had not discussed FCR with their medical team, mainly because they did not consider it a serious issue or were unaware that it could be addressed during consultations. PROMIS scores showed median values of 37.4 for physical health and 43.5 for mental health. HRQoL did not vary according to clinical characteristics or treatments but was associated with age and education. Patients with higher FCR consistently showed poorer HRQoL across all domains (p < 0.001). Conclusions: FCR is highly prevalent and strongly associated with poorer HRQoL, independently of clinical variables. Its identification and management should be systematically integrated into survivorship care for women with breast cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Camejo et al. (2026) studied this question.

synapsesocial.com/papers/6a1a80550307b78509432447https://doi.org/10.1200/jco.2026.44.16_suppl.e12684
Ask AI
Helpful
Bookmark
Share
View Full Paper